These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19499721)

  • 21. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
    Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ;
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.
    Chuang YC; Chang CM; Aradhya S; Nagari B; Pai V; Dartois N; Jouve S; Cooper A
    J Microbiol Immunol Infect; 2011 Apr; 44(2):116-24. PubMed ID: 21439514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tigecycline: a single antibiotic for polymicrobial infections.
    Pankey GA; Steele RW
    Pediatr Infect Dis J; 2007 Jan; 26(1):77-8. PubMed ID: 17195711
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
    Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
    Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.
    Teras J; Gardovskis J; Vaasna T; Kupcs U; Pupelis G; Dukart G; Dartois N; Jouve S; Cooper A;
    J Chemother; 2008 Oct; 20 Suppl 1():20-7. PubMed ID: 19036671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tigecycline: 10 years of history and still in full force].
    Barberán J; Salso S; Alhambra A
    Rev Esp Quimioter; 2015 Apr; 28(2):61-78. PubMed ID: 25904513
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections.
    Wilcox MH
    J Chemother; 2005 Aug; 17 Suppl 1():23-9. PubMed ID: 16285355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New antibiotic approved for MRSA.
    Senior K
    Lancet Infect Dis; 2005 Aug; 5(8):474. PubMed ID: 16094734
    [No Abstract]   [Full Text] [Related]  

  • 29. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
    Meagher AK; Passarell JA; Cirincione BB; Van Wart SA; Liolios K; Babinchak T; Ellis-Grosse EJ; Ambrose PG
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1939-45. PubMed ID: 17353238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.
    Rello J
    J Chemother; 2005 Aug; 17 Suppl 1():12-22. PubMed ID: 16285354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.
    Curcio D
    J Clin Microbiol; 2008 May; 46(5):1892-3. PubMed ID: 18460636
    [No Abstract]   [Full Text] [Related]  

  • 33. New 'superbug' drug launched in the UK.
    Future Microbiol; 2006 Aug; 1(2):151-5. PubMed ID: 17661658
    [No Abstract]   [Full Text] [Related]  

  • 34. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of tigecycline trials announced.
    McConnell J
    Lancet Infect Dis; 2004 Dec; 4(12):717. PubMed ID: 15593443
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
    Sader HS; Mallick R; Kuznik A; Fritsche TR; Jones RN
    Int J Antimicrob Agents; 2007 Dec; 30(6):514-20. PubMed ID: 17959359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital.
    Avkan-Oguz V; Yapar N; Alp-Cavus S; Demir Onder K; Aktas E; Gulay Z; Cakır N
    Int J Clin Pract; 2013 Jun; 67(6):505-11. PubMed ID: 23679904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.
    Heizmann WR; Dupont H; Montravers P; Guirao X; Eckmann C; Bassetti M; García MS; Capparella MR; Simoneau D; Bodmann KF
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tigecycline in critical care.
    Mullangi PK; Pankey GA
    Crit Care Clin; 2008 Apr; 24(2):365-75, x. PubMed ID: 18361951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
    Grolman DC
    Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.